Part of the success of Amgen was using a smaller amount of individuals for clinical trials, and looking at results during the trial instead of an overall evaluation process at the conclusion. It also helps keep the cost of the clinical trials down by conducting studies for biomarkers, or signature proteins, that can offer clues about whether the drug’s working. Clinical trials in smaller numbers are also making their way to many smaller community hospitals as well. BD
Amgen had an epiphany of sorts a little more than four years ago. The worlds largest biotech company decided clinical trials had become too much of a crapshoot, and it needed to shake up its way of developing new drugs. This really isn't unique to Amgen, its more like an industry emergency. Drug companies spent $44.5 billion on research and development last year, yet last year they managed to produce the fewest number of new medicines in 24 years, a big reason why companies are scrambling for a better way.
More data to look at « A Man With A Ph.D.
Amgen Looks to Biomarkers to Boost Its Batting Average in Developing New Drugs:
0 comments :
Post a Comment